NCT06753136Recruiting
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
Treatment of Visceral Localizations With Electrochemotherapy in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype: Monocenter, Single Arm, Clinical Investigation
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous metastases of different tumor histotypes. Although still limited, the various experiences in the treatment of visceral localizations, particularly in liver metastases from colorectal cancer are promising and show that electrochemotherapy is a safe treatment, even in the case of lesions near large vessels or nerves. The investigators therefore propose a clinical investigation with a Medical Device according to EU Regulation 745/2017, using electrochemotherapy (Cliniporator) with bleomycin for the treatment of visceral, primary or secondary, unresectable localizations, with percutaneous or intraoperative technique (laparoscopic or laparotomy), as needed.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 17 Dec 2024
- Start date
- 23 Jul 2025
- Primary completion date
- 31 Jan 2030
- Lead sponsor
- Istituto Oncologico Veneto IRCCS
- NCT number
- NCT06753136
What you commit to
- Study type: Interventional
- Planned participants: 24
- From 23 Jul 2025 to the primary completion date, 31 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant presence of brain, lung, bone metastases
Other illness
- Bleomycin allergy
- Acute lung infections
Other
- Absolute contraindications to invasive procedures
- Uncorrectable coagulation changes
- Absolute contraindications to taking Bleomycin
- Poor respiratory function or pulmonary fibrosis
- Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study
Who the study is looking for
- Male/Female ≥ 18 years
- Ability to understand the proposed treatment and express an informed acceptance by signing the informed consent
- Diagnosis of primary and/or secondary visceral localizations of any histotype
- Patients who are not eligible for standard curative procedures
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istituto Oncologico Veneto Coordinator of this site? Confirm its status | Padova | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.